May 2013 FDA Recall Norpace Cr by Pfizer Inc
D-607-2013 - Failed Dissolution Specification

This Class III drug recall was voluntarily initiated by Pfizer Inc on May 31, 2013 for the product Norpace Cr. The FDA reported the reason for recall as failed dissolution specification. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-607-2013

Reason for Recall
Failed Dissolution Specification
Initiated
05-31-2013
Reported
06-26-2013
Quantity
5,410 botlles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Nationwide and Puerto Rico
Norpace CR (disopyramide phosphate) extended-release capsules USP,150 mg, packaged in a) 100-count bottles (NDC 0025-2742-31), and b) 500-count bottles (NDC 0025-2742-51), Rx only, Distributed by G.D. Searle LLC, Division of Pfizer Inc, NY, NY 10017.

Batch or Lot Expiration Information

Lot# : a) C120138, Exp 07/13; b) C120137, Exp 07/13